A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

NCT05472090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
COVID-19
Long COVID
Long Haul COVID

Interventions

DRUG: TNX-102 SL
DRUG: Placebo SL Tablet

Sponsor

Tonix Pharmaceuticals, Inc.